Core Viewpoint - The financial performance of Shangrong Medical (002551) has significantly declined, with a notable drop in revenue and net profit for the first three quarters of 2025 compared to the previous year [2]. Group 1: Financial Performance - For the first three quarters of 2025, the company's main revenue was 754 million yuan, a decrease of 24.85% year-on-year [2]. - The net profit attributable to the parent company was -35.13 million yuan, representing a decline of 338.5% year-on-year [2]. - The net profit after deducting non-recurring items was -42.33 million yuan, down 1336.59% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 225 million yuan, a decrease of 39.25% year-on-year [2]. - The single-quarter net profit attributable to the parent company was -27.37 million yuan, a decline of 4004.28% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -29.81 million yuan, down 2776.04% year-on-year [2]. - The company's debt ratio was 23.31%, with investment income of 10.20 million yuan and financial expenses of -3.79 million yuan [2]. - The gross profit margin was 14.35% [2]. Group 2: Market Activity - As of January 27, 2026, the stock closed at 3.92 yuan, down 1.51%, with a turnover rate of 3.51% and a trading volume of 214,600 hands, amounting to a transaction value of 83.43 million yuan [1]. - On January 27, the net outflow of main funds was 9.93 million yuan, accounting for 11.9% of the total transaction value, while retail investors had a net inflow of 10.12 million yuan, representing 12.14% of the total transaction value [1].

Group 1 - The core viewpoint of the news is that Shangrong Medical (002551) is expected to report significant losses for the year 2025, with projected net profit losses ranging from 1.2 billion to 1.7 billion yuan [1][3] - On January 23, 2026, Shangrong Medical's stock closed at 3.91 yuan, reflecting a 0.26% increase, with a turnover rate of 1.47% and a trading volume of 90,000 shares, amounting to a transaction value of 35.177 million yuan [1] - The company reported a net inflow of 4.2705 million yuan from major funds on January 23, while retail investors experienced a net outflow of 0.8129 million yuan [1][3] Group 2 - The company announced that the expected loss for the year 2025, attributable to shareholders, is projected to be between 1.2 billion and 1.7 billion yuan, with a non-recurring net profit loss estimated between 1.361926 billion and 1.861926 billion yuan [1][3] - The anticipated losses are primarily attributed to a decrease in hospital engineering projects, lower-than-expected receivables leading to increased bad debt provisions, a decline in revenue from medical consumables exports due to international conditions, rising costs, and increased foreign exchange losses [1][3]

Group 1 - The company expects a negative net profit for the fiscal year 2025, which spans from January 1, 2025, to December 31, 2025 [2] - The financial data related to this profit forecast has not been audited by a registered accounting firm, but preliminary discussions have taken place, and no significant discrepancies were noted as of the disclosure date [2][3] Group 2 - The main reasons for the expected performance decline include a reduction in hospital engineering projects due to industry conditions, leading to decreased revenue from medical engineering services [3] - There has been an increase in bad debt provisions due to lower-than-expected collections from hospital engineering projects [3] - The export business of medical consumables has been negatively impacted by international circumstances, resulting in decreased revenue and increased costs, which have led to a decline in gross profit margin [3] - Currency fluctuations have caused an increase in exchange losses recognized by the company [3] - The company has increased its provisions for asset impairment during this reporting period [3]

Core Viewpoint - Shenzhen Shangrong Medical Co., Ltd. is expected to report significant losses for the fiscal year 2025, primarily due to various operational challenges and external market conditions [1] Financial Performance - The company's stock closed at 3.91 yuan on January 23, 2026, reflecting a 0.26% increase from the previous trading day, with a total market capitalization of 3.306 billion yuan [1] - The projected net profit attributable to shareholders for 2025 is expected to be between -170 million yuan and -120 million yuan, while the net profit after deducting non-recurring gains and losses is forecasted to be between -186.1926 million yuan and -136.1926 million yuan [1] Reasons for Losses - The anticipated losses are attributed to several factors, including: - A decrease in hospital engineering projects - Lower-than-expected receivables leading to increased bad debt provisions - A decline in revenue from medical consumables exports due to international market conditions, alongside rising costs - Increased foreign exchange losses due to currency fluctuations - Higher asset impairment provisions [1]

Group 1 - The company operates in the medical products, medical services, and health industry sectors [7] - The company's performance has been negatively impacted by a decrease in hospital engineering projects due to industry conditions, leading to a reduction in medical engineering service revenue [7] - The company has increased its provision for bad debts due to lower-than-expected hospital project payments [7] Group 2 - The export business of medical consumables has faced challenges due to international circumstances, resulting in decreased revenue and increased costs, which have led to a decline in gross profit margin [7] - Currency fluctuations have contributed to an increase in exchange losses recognized by the company [7] - The company has also increased its asset impairment provisions during the reporting period [7] Group 3 - Historical net profit and non-recurring profit growth rates show significant fluctuations, with a notable decline in 2022 and projections for 2023 indicating continued challenges [10] - The company's net profit and non-recurring profit have shown negative trends in quarterly changes, indicating ongoing financial difficulties [10]

Core Viewpoint - Shangrong Medical is expected to report a net profit loss of 136 million to 186 million yuan for the full year of 2025, primarily due to adverse industry conditions and operational challenges [1] Group 1: Performance Forecast - The company anticipates a net profit loss of 136 million to 186 million yuan after deducting non-recurring items for the year 2025 [1] - The decline in performance is attributed to a reduction in hospital engineering projects and corresponding service revenue [1] Group 2: Financial Results - For the first three quarters of 2025, the company's main revenue was 754 million yuan, a year-on-year decrease of 24.85% [1] - The net profit attributable to shareholders was -35.13 million yuan, a year-on-year decline of 338.5% [1] - The non-recurring net profit was -42.33 million yuan, a year-on-year decrease of 1336.59% [1] Group 3: Quarterly Performance - In Q3 2025, the company's single-quarter main revenue was 225 million yuan, down 39.25% year-on-year [1] - The single-quarter net profit attributable to shareholders was -27.37 million yuan, a year-on-year decline of 4004.28% [1] - The single-quarter non-recurring net profit was -29.81 million yuan, a year-on-year decrease of 2776.04% [1] Group 4: Financial Ratios and Other Metrics - The company's debt ratio stands at 23.31% [1] - Investment income reported was 10.20 million yuan, while financial expenses were -3.79 million yuan [1] - The gross profit margin is recorded at 14.35% [1]

Core Viewpoint - Shangrong Medical is expected to report a net profit loss of between 120 million to 170 million yuan for the full year of 2025 due to various adverse factors affecting its operations [1] Group 1: Performance Forecast - The company anticipates a net profit loss of 120 million to 170 million yuan for 2025 [1] - The decline in performance is attributed to a reduction in hospital engineering projects and corresponding medical engineering service revenue [1] Group 2: Financial Results - For the first three quarters of 2025, the company's main revenue was 754 million yuan, a year-on-year decrease of 24.85% [1] - The net profit attributable to shareholders was -35.13 million yuan, a year-on-year decline of 338.5% [1] - The non-recurring net profit was -42.33 million yuan, a year-on-year decrease of 1336.59% [1] Group 3: Quarterly Performance - In Q3 2025, the company's single-quarter main revenue was 225 million yuan, down 39.25% year-on-year [1] - The single-quarter net profit attributable to shareholders was -27.37 million yuan, a year-on-year decline of 4004.28% [1] - The single-quarter non-recurring net profit was -29.81 million yuan, a year-on-year decrease of 2776.04% [1] Group 4: Financial Ratios and Other Metrics - The company's debt ratio stands at 23.31% [1] - Investment income reported was 10.20 million yuan, while financial expenses were -3.79 million yuan [1] - The gross profit margin is recorded at 14.35% [1]

Core Viewpoint - The company, Shangrong Medical, anticipates a significant decline in net profit for the fiscal year 2025, projecting a loss between 170 million to 120 million yuan compared to a profit of 22.28 million yuan in the previous year [1] Financial Projections - The expected net profit attributable to shareholders is projected to be between -170 million to -120 million yuan, a stark contrast to the previous year's profit of 22.28 million yuan [1] - The net profit after excluding non-recurring gains and losses is forecasted to be between -186 million to -136 million yuan, compared to 11.6581 million yuan in the same period last year [1] - The basic earnings per share are estimated to be between -0.2011 yuan to -0.142 yuan, down from 0.0264 yuan per share in the prior year [1]

Financial Performance Expectations - The company expects a net profit in the range of -¥17,000,000 to -¥12,000,000 for the fiscal year 2025, compared to a profit of ¥2,228,200 in the same period last year[4] - The net profit after deducting non-recurring gains and losses is projected to be between -¥18,619,260 and -¥13,619,260, down from ¥1,165,810 in the previous year[4] - Basic earnings per share are expected to be between -¥0.2011 and -¥0.1420, compared to ¥0.0264 in the same period last year[4] Revenue and Project Performance - The decrease in performance is primarily due to a reduction in hospital engineering projects, leading to decreased revenue from medical engineering services[6] - Revenue from medical consumables exports has decreased due to international market conditions, resulting in lower gross margins[6] Financial Provisions and Losses - The company has increased its provision for bad debts due to lower-than-expected collections from hospital engineering projects[6] - The company has increased its asset impairment provisions during the reporting period[7] - Exchange rate fluctuations have led to increased foreign exchange losses for the company[7] Reporting and Investor Guidance - The financial data presented is preliminary and has not been audited, with final figures to be confirmed in the 2025 annual report[8] - Investors are advised to refer to designated media for official disclosures and to be aware of investment risks[9]

Group 1 - The stock price of Shangrong Medical (002551) closed at 3.85 yuan on January 20, 2026, with a slight increase of 0.26% and a turnover rate of 2.05% [1] - The trading volume was 125,500 hands, with a total transaction amount of 48.0653 million yuan [1] - On January 20, the net inflow of main funds was 141,700 yuan, accounting for 0.29% of the total transaction amount, while retail investors had a net inflow of 2.4133 million yuan, representing 5.02% of the total [1] Group 2 - For the first three quarters of 2025, Shangrong Medical reported a main revenue of 754 million yuan, a year-on-year decrease of 24.85%, and a net profit attributable to shareholders of -35.1253 million yuan, down 338.5% [2] - In Q3 2025, the company’s single-quarter main revenue was 225 million yuan, a decline of 39.25%, with a net profit of -27.367 million yuan, a decrease of 4004.28% [2] - The company’s debt ratio stands at 23.31%, with investment income of 10.2049 million yuan and financial expenses of -3.7891 million yuan, while the gross profit margin is 14.35% [2]